SciELO - Scientific Electronic Library Online

 
vol.15 número1Método de análisis de turns: Variables mas usadasClonidina oral en la medicación preanéstesica del paciente hipertenso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Investigaciones Biomédicas

versión impresa ISSN 0864-0300versión On-line ISSN 1561-3011

Resumen

SELLEN CROMBET, Joaquín et al. Regresión de hipertrofia ventricular izquierda con inhibidores de la enzima de conversión de angiotensina. Rev Cubana Invest Bioméd [online]. 1996, vol.15, n.1. ISSN 0864-0300.

An assessment was made on the regression of left ventricular hypertrophy in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors during 6 months. The heart anatomy and function were studied by echocardiogram. Thirty nine patients finished the treatment. Feminine sex and white race, with an average age of 47 years old, were prevailing. The 13 % were mildly hypertensive; 51 % were moderately hypertensive, and 36 % were severe. The figures of arterial pressure significantly decreased (p < 0,00001). At the echocardiogram, mass, mass index, posterior wall septum and meridional stress, decreased from the left ventricle. The concentric hypertrophy was the most frequent, followed by concentric remodeling. Six months later, the normal geometry was reached in the 12,83 % of the sample. It is concluded that monotherapy with these drugs is effective to control arterial hypertension, and it causes the anatomical regression of the ventricular growth in a short period.

Palabras clave : HYPERTROPHY, LEFT VENTRICULAR [drug therapy]; HYPERTENSION [drug therapy]; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS [therapeutic use]; ECHOCARDIOGRAPHY.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons